Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Latest advances in myelofibrosis treatment

Andrew Kuykendall • 8 Jun 2021
EHA 2021
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Ruxolitinib
JAKARTA2

Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, gives an overview of the latest treatment advances for myelofibrosis, highlighting the use of ruxolitinib in the frontline and fedratinib in the second-line and the need for a broader range of options. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Andrew Kuykendall

1:44
Predicting thrombocytopenia as a result of ruxolitinib treatment in MF
Andrew Kuykendall • 27 Nov 2023
2:06
Thromboembolic event rates in patients with PV: a real-world analysis
Andrew Kuykendall • 27 Nov 2023
2:03
Preliminary results of a Phase II study of fedratinib in patients with MDS/MPN and CNL
Andrew Kuykendall • 27 Nov 2023
1:40
Challenges and options for patients with hydroxyurea-resistant PV
Andrew Kuykendall • 27 Nov 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals